Inovio's DNA-Encoded Monoclonal Antibody (dMAb(TM)) Platform L...
PLYMOUTH MEETING, Pennsylvania, Jan. 7, 2019 /PRNewswire-AsiaNet/ -- - First Human dMAb Study Will Target Zika Infection Inovio Pharmaceuticals, Inc. (NASDAQ: INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced today the initiation of the first human study of its DNA-enc...
Read more https://view-release/?pr-id=76969